WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question

WHO’s chief scientist said “We owe it to patients to have a definitive answer on whether or not a drug works.'

Reuters June 04, 2020 11:29:22 IST
WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question

The World Health Organization will resume its trial of hydroxychloroquine for potential use against the coronavirus, its chief said on Wednesday, after those running the study briefly stopped giving it to new patients over health concerns.

The U.N. agency last month paused the part of its large study of treatments against COVID-19 in which newly enrolled patients were getting the anti-malarial drug to treat COVID-19 due to fears it increased death rates and irregular heartbeats.

The study continued with other medicines.

WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question

A file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. On Tuesday, June 2, 2020, concerns are mounting about studies in two influential medical journals on drugs used in people with coronavirus, including one that led multiple countries to stop testing a malaria pill. Image credit: AP Photo/John Locher

But the WHO’s director-general, Tedros Adhanom Ghebreyesus, said its experts had advised the continuation of all trials including hydroxychloroquine, whose highest-profile backer for use against the coronavirus is US President Donald Trump.

“The executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial,” Tedros told an online media briefing, referring to WHO’s initiative to hold clinical tests of potential COVID-19 treatments on some 3,500 patients in 35 countries.

The WHO’s decision to suspend its trial prompted others to follow suit, including Sanofi, which said on 29 May it was suspending recruitment for its trials. A Sanofi spokesman said the company would review available information and run consultations in the coming days to reassess its position following the WHO’s latest decision on Wednesday.

The WHO’s chief scientist, Soumya Swaminathan, called for other trials of the drug to proceed. “We owe it to patients to have a definitive answer on whether or not a drug works,” she said, adding that safety monitoring should also continue.

Swaminathan said the WHO would be keen to see more results of clinical trials of Avifavir, a drug she said would be used to treat COVID-19 in Russian hospitals “very soon”.

In the same virtual briefing, WHO officials said they were especially worried about outbreaks in Latin America and in Haiti, one of the world’s poorest nations, where infections have been spreading rapidly.

The coronavirus has infected almost 3 million people in the Americas and more than 6.43 million worldwide.

Also Read: 

Hydroxychloroquine sustained dose and PPE can reduce COVID-19 risk in healthcare workers, ICMR study says

Two studies that showed Hydroxychloroquine's negative effects on COVID-19 patients are being called into question

Updated Date:

also read

Potential COVID-19 vaccine candidate Zydus gets nod of approval to begin human trials in India
India

Potential COVID-19 vaccine candidate Zydus gets nod of approval to begin human trials in India

The vaccine showed a “strong immune response” in animal studies and will begin human trials this month in over 1,000 subjects in multiple sites.

Premier League: Watford trio left out of squad for Southampton clash for breaching coronavirus lockdown rules
Sports

Premier League: Watford trio left out of squad for Southampton clash for breaching coronavirus lockdown rules

Andre Gray, Nathaniel Chalobah and Domingos Quina have been left out of the Watford squad for the Southampton clash as a healthy precautionary measure.

Public mobility in COVID-19 'unlock': Indians return to workplaces with gusto, slow to resume retail and recreation, data shows
India

Public mobility in COVID-19 'unlock': Indians return to workplaces with gusto, slow to resume retail and recreation, data shows

Even though workplace activity has seen significant increases since the first COVID-19 lockdown, economic activity can only recover if people are going out and buying products